Rezvoglar Price and Insurance Coverage
The price of Rezvoglar, a biosimilar to insulin glargine, can vary depending on factors such as pharmacy, location, and insurance coverage. Without insurance, the average retail price for a 10-milliliter (mL) vial of Rezvoglar can be approximately \$237. However, a 5-pack of 3-mL prefilled pens may cost around \$366. These figures represent out-of-pocket costs and are subject to change [1].
How Does Insurance Affect Rezvoglar Cost?
Insurance plans often have different coverage levels for prescription drugs. For Rezvoglar, copayments can range from \$0 to \$25 for a 30-day supply if covered by a plan. Some plans may require prior authorization or have a preferred pharmacy network, which can influence the final cost [1].
What is Rezvoglar Used For?
Rezvoglar is a long-acting insulin used to manage blood sugar levels in adults and children aged 6 years and older who have diabetes mellitus. It works by providing a steady dose of insulin over a 24-hour period, helping to control hyperglycemia [2].
When Does Rezvoglar's Patent Expire?
As a biosimilar, Rezvoglar's market entry is dependent on the patents of the reference product, Lantus (insulin glargine) [3]. Patent expiration dates for biosimilars are complex and can involve multiple patents and legal challenges. Information on specific patent expiry timelines for biosimilar insulin glargine products can be found on resources like DrugPatentWatch.com [4].
How Does Rezvoglar Compare to Lantus?
Rezvoglar is a biosimilar to Lantus, meaning it is a highly similar biological product to the reference medicine, with no clinically meaningful differences in terms of safety, purity, and potency. The U.S. Food and Drug Administration (FDA) approves biosimilars based on rigorous scientific evidence demonstrating this similarity. While therapeutically equivalent, slight differences in inactive ingredients may exist between biosimilars and their reference products [3].
Who Manufactures Rezvoglar?
Rezvoglar is manufactured by Eli Lilly and Company [1].
What Are the Potential Side Effects of Rezvoglar?
The most common side effects associated with Rezvoglar, similar to other long-acting insulins, include low blood sugar (hypoglycemia), weight gain, and allergic reactions. Hypoglycemia can manifest as dizziness, sweating, confusion, and rapid heartbeat. Other potential side effects may include injection site reactions, lipodystrophy (changes in fat tissue at the injection site), and edema (swelling) [2].
How is Rezvoglar Administered?
Rezvoglar is administered by subcutaneous injection into the abdomen, thigh, or upper arm. It should not be injected into a vein or muscle. The dosage and timing of administration are determined by a healthcare provider based on individual needs [2].
Can Biosimilars Be Cheaper Than Brand-Name Drugs?
Biosimilars are generally expected to be less expensive than their reference biologic products. This cost reduction is a key driver for their development and adoption, aiming to increase patient access to important therapies [3].
Sources:
1. https://www.goodrx.com/rezvoglar
2. https://www.rezvoglar.com/
3. https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-insulin-glargine-product-us
4. https://www.drugpatentwatch.com/